Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

A 2-part Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) Administered to Adults With Major Depressive Disorder at Imminent Risk of Suicide

To see complete record on, please visit this link

Id: NCT04669665

Organisation Name: Seelos Therapeutics, Inc.

Overal Status: Recruiting

Start Date: December 17, 2020

Last Update: July 27, 2022

Lead Sponsor: Seelos Therapeutics, Inc.

Brief Summary: The purpose of the study is to evaluate the efficacy, safety, and tolerability of SLS-002 (intranasal racemic ketamine) in addition to standard of care on symptoms of Major Depressive Disorder (MDD) and suicidality, in participants who are assessed to be at imminent risk for suicide, as measured by the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) total score at 24 hours post first dose.

  • Depressive Disorder, Major
  • Suicidal

Total execution time in seconds: 0.29180192947388